Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 20, 2024Deleted JournalOpen Access

Tailoring Caplacizumab Administration Using ADAMTS13 Activity for Immune-mediated Thrombotic Thrombocytopenic Purpura

View Full Paper
Ask AI
Bookmark
Share

Authors

SYSean G. YatesSHSandra L. HofmannIIIbrahim F. Ibrahim

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yates et al. (2024) studied this question.

synapsesocial.com/papers/68e694aeb6db64358761abfahttps://doi.org/10.1016/j.bvth.2024.100010
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Race, rituximab, and relapse in TTP2022 · 42 citations
  2. 2A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP2020 · 192 citations
  3. 3Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis2022 · 27 citations
  4. 4Redefining outcomes in immune TTP: an international working group consensus report2021 · 226 citations
  5. 5Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura2020 · 84 citations